A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Bacterial Enteritis

Interventions

DRUG

14C-OPS-2071

Subjects will swallow Single 25 mL of suspension containing 50 mg of 14C-OPS-2071 directly.

Trial Locations (1)

Leeds